Sexual delinquency and Parkinson's disease

被引:32
作者
Berger, C
Mehrhoff, FW
Beier, KM
Meinck, HM
机构
[1] Heidelberg Univ, Neurol Klin, D-69120 Heidelberg, Germany
[2] Humboldt Univ, Inst Sexualmed Charite, Berlin, Germany
来源
NERVENARZT | 2003年 / 74卷 / 04期
关键词
sexual delinquency; Parkinson's disease; L-dopa; dopamine agonists;
D O I
10.1007/s00115-003-1505-6
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The risk of aberrant sexual behaviour such as hypersexuality, exhibitionism, or pederasty may be underestimated in Parkinson's disease and its therapy with high-dosage L-dopa or dopamine agonists. We describe two legal cases which are representative of the forensic assessment of these side effects. The first case brought to court was a 45-year-old man suffering for 20 years from Parkinson's disease who developed hypersexuality and exhibitionism under high-dose therapy with ropinirol. The second patient, a 57-year-oid man with an 11-year history of Parkinson's disease, developed increased libido and pederasty under therapy with L-dopa and bromocriptine. We discuss the present literature concerning hypersexual and sexually deviant behaviour in Parkinson's disease and dopaminergic therapy in the German legal context. Doctors treating Parkinson patients should be aware of increased sexual impulses or reduced behavioural control and ask specifically about them during anamnesis, and counteractive therapeutic strategies should be considered to prevent the occurrence of illegal sexually aberrant behavioural disorders.
引用
收藏
页码:370 / 375
页数:10
相关论文
共 30 条
[21]   Long-term follow up of subthalamic nucleus stimulation in Parkinson's disease [J].
Romito, LMA ;
Scerrati, M ;
Contarino, MF ;
Bentivoglio, AR ;
Tonali, P ;
Albanese, A .
NEUROLOGY, 2002, 58 (10) :1546-1550
[22]  
ROXIN C, 1992, STRAFRECHT ALLGEMEIN, V1
[23]   Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease [J].
Ruggieri, S ;
DePandis, MF ;
Bonamartini, A ;
Vacca, L ;
Stocchi, F .
CLINICAL NEUROPHARMACOLOGY, 1997, 20 (03) :204-209
[24]   Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease [J].
Sakakibara, R ;
Shinotoh, H ;
Uchiyama, T ;
Sakuma, M ;
Kashiwado, M ;
Yoshiyama, M ;
Hattori, T .
AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL, 2001, 92 (1-2) :76-85
[25]  
SCHONKE A, 2001, STRAFGESETZBUCH KOMM, P20
[26]   Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience [J].
Trosch, RM ;
Friedman, JH ;
Lannon, MC ;
Pahwa, R ;
Smith, D ;
Seeberger, LC ;
O'Brien, CF ;
LeWitt, PA ;
Koller, WC .
MOVEMENT DISORDERS, 1998, 13 (03) :377-382
[27]   HYPERSEXUALITY WITH ANTIPARKINSONIAN THERAPY [J].
UITTI, RJ ;
TANNER, CM ;
RAJPUT, AH ;
GOETZ, CG ;
KLAWANS, HL ;
THIESSEN, B .
CLINICAL NEUROPHARMACOLOGY, 1989, 12 (05) :375-383
[28]   HYPERSEXUALITY - A COMPLICATION OF DOPAMINERGIC THERAPY IN PARKINSONS-DISEASE [J].
VOGEL, HP ;
SCHIFFTER, R .
PHARMACOPSYCHIATRIA, 1983, 16 (04) :107-110
[29]   Sexuality in women with Parkinson's disease [J].
Welsh, M ;
Hung, L ;
Waters, CH .
MOVEMENT DISORDERS, 1997, 12 (06) :923-927
[30]  
WERMUTH L, 1995, ACTA NEUROL SCAND, V91, P453